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Hyperforin: A lead for Antidepressants 
 







Depression is a complex but treatable disorder if 
diagnosed appropriately. However, despite the 
advances in the understanding of the molecular basis 
of this disorder and the vast range of medication, 
psychotherapy and electroconvulsive therapy, very 
safe and effective drug to treat this disease is still 
being sought. Several studies suggest that St.John’s 
wort (Hypericum perforatum L.) has phloroglucinol 
derivative, hyperforin, exhibiting antidepressant 
activity. This bioactive component can be exploited to 
create a major shift in the safer treatment of 
depression. 
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Introduction  
 
Depression continues to be a major cause of 
disability throughout the world affecting 
about 121 million people worldwide, the 
4
th
 leading contributor to the global burden of 
disease (DALYs) in 2000 and have a huge 
societal impact
1
. Depression can lead to 
suicide, a tragic fatality associated with the 
loss of about 850,000 lives every year. It is 
associated with distress, despair, 
hopelessness and low energy.  
 
Treatment of depression by safe and 
effective antidepressants like SSRIs is a 
major achievement of 20
th
 century 
psychophar-macology. Global sales of 
antidepressant now exceed US $ 10 billion 
annually, making them the only most 
important group of psychopharmaceuticals, 
and include some of most widely used 
prescription drugs (e.g. Fluoxetine; Prozac). 
Strangely enough in 2005, the FDA adopted 
a "black box" warning label on all 
antidepressant medications to alert the 
public about the potential increased risk of 
suicidal thoughts or attempts in children and 
adolescents taking antidepressants (based 
on controlled clinical trails conducted by FDA 
in 2004)
2
. However, these conventional 
antidepressants have some other limitations: 
 
• It is very difficult to prescribe suitable 
effective antidepressant judiciously, while 
starting the treatment for a particular 
patient i.e. may have to switch to a 
different medication if first one was not 
working. 
• Antidepressants may cause mild side 
effects in some people. 
• Currently available antidepressant 
requires administration for at least 2-4 
weeks to experience full therapeutic effect 
or delayed time of onset of 
antidepressant. 
• People taking monoamine oxidase 
inhibitors (MAOIs) must adhere to 
significant food and medicinal restrictions 
to avoid potentially serious interactions. 
• Certain populations of patient are resistant 
to current therapies. 
 
These have led to huge demands of safer 
and effective antidepressant that address 
these limitations, which have led to 
popularity of ancient herbal medicine 
St.John’s wort and their  preparations. 
 
St John’s wort: Phytopharmacotherapy of 
Depression 
 
The ethnopharmacological uses and huge 
prescriptions of St.John’s wort (Hypericum 
perforatum L) - best known as ‘Nature’s 
Prozac (fluoxetine)
3
 - established this 
herbal drug as natural antidepressant. All 
critical analysis on commercial and other 
information available on sales of herbal 
medicines in the USA shows that, for the first 
eight months of 1998, it ranked second to 
Ginko as the best selling herbal drug, with 
retail sales valued at over $200 million
4
.  In 
Germany, St John wort is the leading 
treatment for depression, outselling 
flouxetine (Prozac) by a factor of four 
5
; 
some reports estimated 20 times more. 
 
St John’s wort consists of the leaves and 
flowering tops of Hypericum perforatum L 
(Family: Clusiaceae), an herbaceous 
perennial weed commonly found in Asia, 
Europe and USA
6
. The common name of 
plant is due to the fact that it flowers around 




. Paracelsus, a 
Swiss physician in 1525 discovered its use in 
psychiatric disorder (neuralgia, anxiety, 
neurosis and depression) 
8
. The plant has 
long been established in ancient Greece for 
its other medicinal attributes and has also 










perforatum L is also used in traditional 
medicines for its anticonvulsant property
15
. 
The plant has also been employed as an 
antihelmentic emmenagogue. An oil known 
as St John’s wort oil (Oleum hyperici) is 
prepared by infusing the fresh flowers in 
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Hussain et al                                             Hyperforin: A lead for Antidepressants 
 
Int J Health Res, March 2009; 2(1):  17 
olive oil; used externally in wounds, sores, 
ulcers, swelling and rheumatism and 
lumbago
16
. An ointment for use as hair-
restorer has been prepared from aqueous 
extracts of the plant
17
. Leaves of the plants 
are widely used for diarrhoea, piles, uterine 
and rectal prolapse. The decoction is 
reported to treat bleeding. In domestic milch 
animals, the plant is reported to affect 
adversely the quantity and flavour of milk
18. 
The phytochemical analysis and biological 
activity data suggested a possible use of 
Hypericum perforatum L extracts in the 





Phytochemistry of Hypericum 
 
The phytochemistry of Hypericum has 
engaged the attention of many scientists due 
to its wide variety of constituent with 
biological activity. It contains anthraquinone / 
naphthadianthrones (principally hypercin and 
pseudohypercin), prenylated phloroglucinol 
derivatives (hyperforin, 2.0 - 4.5%, principal 
lipophilic compound of hydro-alcoholic 
extracts, phloroglucinol skeleton with 
lipophlic isoprene chains), flavonoids (such 
as kaempferol, luteolin and quercetin), and 
volatile oil (up to 0.35%, saturated 
hydrocarbon). Some amino acids, vitamin C, 
tannin and carotenoids have also been 
reported 
9
 to be present in the plant. The 
concentration and proportion of different 
constituents in the plant are closely related to 
harvesting period, drying process and 
storage conditions. Hyperforin content has 
been reported to increase considerably 
during fruit development; it increases from 
2% (flower) to 4.5% (fruit) of dry weight. The 
crude drug (fruit) harvested at the beginning 





Out of all components hypercin and 
hyperforin (figure 1) were more interestingly 
focused, due to their clinical significance. 
However several authors have reported 
flavonoids such as quercetin as anti-
inflammatory
21
. Both hyperforin {(1S,5S, 
7S,8R)-4-hydroxy-8-methyl-3,5,7-tris(3 meth-
yl but-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-
methylpropanoyl) bicycle [3.3.1] non-3-ene-























Figure 1: Chemical structures of hypericin and hyperforin, biologically active constituents of St 
John’swort 
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hodianthrone, C30H16O8, a red dye obtained 
from translucent black dots on the surface of 
calyx and corolla, generally decompose 
above 330 °C) were initially thought to have 
MAO-inhibitory antidepressant property 
16,22,23
. Hypercin, a phototoxin has also been 
found to prevent insects from avoiding 
phototoxicity
24
. Many synthetic hypercin were 
also synthesized and subjected to clinical 
trails for the treatment of AIDS.  
 
Many experimental and clinical studies have 
confirmed that the antidepressant property of 
St John’s wort is not due to hypercin but 
hyperforin
9, 25 - 29
 because: 
 
• Hypercin shows in-vitro MAO-inhibition 
only at concentration (EC50 >10 mg/ml), 




• Acute or chronic treatment with St. 









Surprisingly, a study by Kumar et al,
34 
on 
Indian variety of H. perforatum (standardized 
for hyperforin) showed no MAO-A and B 
inhibitory activities. Many recent reviews 





Recently, many studies have raised the 
question of instability of H. perforatum L 
formulation, owing to degradation of 
hyperforin. The compound, hyperforin, is 
more prone to air oxidation, unstable in light 
and most organic solvents
33
. One study 
showed a new degradation product of 
hyperforin namely, deoxyfurohyperforin A, 
together with the previously identified 
furohyperforin, furoadhyperforin, furohyper-
forin A, pyrano[7,28-b] hyperforin  and 3 - 
methyl - 4, 6 - di (3 - methyl - 2 - butenyl) - 2 
- (2 - methyl - 1 -oxopropyl) - 3 - (4 - methyl - 




Mechanism of action 
 
The mechanism of action of antidepressant 
activity of hyperforin is still not clear, though 
the following hypotheses are supported by 
many publications: 
 
• Hyperforin was found to be potent uptake 
inhibitor of 5 - HT, Dopamine (DA), 








• Hyperforin induces changes in the rat and 
human electron encephalogram (EEG) 




• Single 300 mg/kg dose of hypericum 
extract reaches the plasma concentration 




• Hyperforin increases the extracellular 
brain concentration of (5-HT, DA, NA and 




However one publication which indicated that 
“Hypericum does not inhibit brain serotonin 
uptake for inducing antidepressant-like 
activity in rats” suggests that a mechanism, 
other than inhibition of 5 - HT uptake, may be 
responsible for its antidepressant-like activity 
41
. A recent study hows that hyperforin 
induces sodium influx via Transient Receptor 
Potential Channel (TRPC) mediated by 
activation of tyrosine kinase receptors and 
phospholipase C in PC12 cells. This sodium 
influx leads to an efficient inhibition of 
serotonin transporters and to an elevation of 
synaptic serotonin levels. 
 
So antidepressant activity of hyperforin is 
mediated through transduction pathways. 
There are indications that the path of novel 
drug target for new class of antidepressants 
through the activation of TRPC channels 
e2110p86 
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Although various preclinical studies have 
revealed that the antidepressant effect is still 
uncertain, and needs to be proved by further 
experiments, there is not a shadow of doubt 
in our mind that lipophylic acyl phloroglucinol 





Hyperforin has been demonstrated to 
produce some side effects (Table 1). These 
include 
 
• Photosensitivity that provokes changes in 
skin pigmentation when it is exposed to 
sun. 
• Serotonergic syndrome when 
administered simultaneously with 
paroxetine, a selective serotonin reuptake 
inhibitor or in sensitive patients. 
• Mania episodes associated with the 
administration to patients more than 50 
year old. 
• Acute nephropathy after exposure to sun. 
• Hepatic cytochrome P450 pathway 
activation, producing significantly 
decreased plasma concentration of drugs 
and reducing their therapeutic actions. 
• Hypericin can induce changes in lens 
protein from calves that could lead to the 
formation of cataract in the presence of 
light. 
 
Future Prospects – Semi-synthetic 
derivatives of Hyperforin 
 
The ethnopharmacological uses and several 
findings of St John’s Wort, through the 
centuries, has provided a lead which can be 
exploited for the development of newer 
antidepressants having improved efficacy 
and lesser toxicity. However, various 
successful attempts have been made to 
synthesize stable hyperforin derivatives 
(salts and esters) e.g. its dicyclohexyl 
ammonium salts (Cervo et al
58




IDN 5491 (hyperforin-trimethoxy benzoate, a 
semi-synthetic ester)
60
. IDN 5491 has been 
evaluated for antidepressant activity by 




The efficacy and lack of toxicity of hyperforin 
make it an interesting lead for the synthesis 
of structural analogs. This approach has 
proved very productive, and has resulted in 
the production of wide range of very active 
synthetic products, many of which can be 
used in formulation, since they are more 
stable to light and stable for longer time. The 
first synthetic direction is to modify the 
phenolic moiety. Other modifications are 
more substantial and consist of replacing the 
alkyl side chain by heterocyclic structure: 
furyl, pyridyl residue that could produce a 




Though St John's wort (Hypericum 
perforatum) has several side effects (Table 
1) and drug interactions (Table 2), the plant 
has afforded an effective arsenal against 
depression. Therefore, it is crucial to identify 
the pharmacological interactions of 
Hypericum with other treatments, in order to 
assess the tolerability of bioactive 
compounds and to establish with what extent 
of safety these extracts can be administered 




We are grateful to the Dr Sheeba Fareed, 
Assistant Professor, Faculty of Pharmacy, 
Integral University, Lucknow for his 
assistance and encouragement. We extend 
our sincere thanks to Dr M Sharyar 
Department of Pharmaceutical chemistry, 
Faculty of Pharmacy, Jamia Hamdard, New 
Delhi, for critically reading the manuscript 





Hussain et al                                             Hyperforin: A lead for Antidepressants 
 
Int J Health Res, March 2009; 2(1):  20 
Table 1: Some effects of hyperforin 
 
Biological effects Mechanism References 
Antitumour effect 
Competitive inhibition of cytochrome P450 
isoform CYP1A1 
43, 44 
Proapoptotic effect Release of cytochrome c from mitochondria 
45 
Antimetastasic effect Inhibition of ERK ½ phosphorylation 
46 
Anti-inflammatory effect COX-1 and 5-LO inhibition 
47 
Pro-inflammatory effect 
Promotor activation through AP-1 dependent 
mechanism 
48 
Antiangiogenic effect Inhibition of endothelial cell growth 
46 
Antibacterial effect  
(Active against multiresistant S.aureus 
and other gram positive bacteria) 
No exact mechanism 
49 
Other neurological effects 
i.Modulation of β-amyloid secretion 
ii.Modification of neural membrane 
fluidity 




Increase in the stimulation of fibroblast 




Table 2: Drug-drug interactions 
 
Co-medication Interaction Possible mechanism References 
Digoxin Lowering of plasma 
digoxin 
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